MarkPap Technology

1
MarkPap Technology PAST, PRESENT AND
FUTURE BioSciCon, 2007
2
BioSciCon, Inc.

• BioSciCon is a women-owned small business
  company that has developed and has rights to
  manufacture, market and sale patented
  biomarker-based MarkPap technology products
  intended for cytological early detection of
  cervical cancer/pre-cancer. MarkPap technology
  is more accurate, faster and less costly than
  current Pap test technologies.

3
MarkPap technology Biomarker makes a
difference

• MarkPap biomarker is cytoplasmic
  expression of genetic changes in cervical cells
  during
• transformation from normal to pre-malignant
  (dysplastic) and malignant, with or w/o HPV
  infection. When visualized with MarkPap test
  biomarker appears as a red pigment flagging only
  abnormal cells.

4
MarkPap test applied in Pap test as a new
ancillary method
Abnormal specimen, ASC-H. Three small abnormal
(red) cells among several normal
cells. Screening magnification (left).
Diagnostic magnifications (right). Abnormal
cells cannot be missed!
5
Biomarker is positive in cancer and HPV induced
abnormal cells

• MarkPap smear from a patient with invasive
  cervical carcinoma HPV positive.
• Red biomarker is positive in all abnormal cells
  where micro-vacuolization and dysplastic features
  are present together

6
MarkPap screening and HPV vaccines

• Cervical cancer was the major killer of women
  with malignant diseases. Measures for prevention
  and control, such as mass screening with low-cost
  and accurate methods such as MarkPap, with added
  benefit of HPV vaccines, raise hopes for
  cervical cancer eradication in the years to come.

7
CLINICAL TRIALS RESULTS
2,000 s/s NEW CTR-1 Pap CTR-2 LBP Advantage
Ancillary CAP Pap ThP CAPPAP
MarkPap CAPPAP Pap ThP D-Ac, Se, FN
Diagnostic Accuracy 0.93 0.51 0.82 1.811.6
Sensitivity 0.88 0.51 0.8 1.711.5
False negative 4 18 17 154
8
Intellectual PropertyMarket protection

• MarkPap is currently protected
• 1. Parent patent US PTO 6,143,512
• Granted November 2000
• 2. Patent pending
• 3. International Application (PCT 2004)
• 4. Trademark MarkPap
• Continuing developments
• 5. Digital MarkPap (TelePap)
• 6. MarkPap for home self-testing (HomePap)

9
Competitive MarkPap advantages on the market

• Better accuracy for lower cost
• Better productivity for less liability
• Mass cervical cancer screening worldwide with
  HomePap and TelePap
• Huge societal benefit saving womens lives
  with enormous market and incredible potential for
  profit .
• www.bioscicon.com

10
Market Opportunity WORLD1.7 billion women at
risk

• Developing countries
• 1,400 M women at risk
• 100 M test per year
• Outreach 6.5
• China
• 300 M women at risk
• 72 M test and growing
• Outreach 24
• US EU
• 250 M women at risk
• 95 M tests annually
• 3-5 B dollars market
• Outreach 80 at 3 years

China 300M Risk
US/EU 250M Risk
Developing Countries 1.4 Billion Women at Risk
11
Returns to investors

• Negotiable terms for investment
• Percent of profit on sales of the product
  (royalty)
• Percent interest in the MarkPap LLC (equity
  investment)
• Interest on investment
• BioSciCon offers all options to investors.

12
MarkPap technology in the next decade

• Towards this vision, we are developing a
  palette of products which are unique because they
  are based on the proprietary biomarker. They
  include new types of specimen collection (MarkPap
  Self), digital imaging for fast, reliable and
  low-cost diagnosis at distance (MarkPap Digital)
  and automation for specimen processing, reading
  and interpretation (MarkPap Auto). New products
  as MarkPap Cervical Cell Bank are envision to
  provide material for further basic research and
  new drug development

13
BioSciCon in the next decade

• BioSciCon ultimate goal is the HomeTelePap test
  for global cervical cancer screening, monitoring
  of the effects of HPV vaccination and saving
  thousands of womens lives.
• The business arm MarkPap LLC to manufacture,
  market, distribute and sale MarkPap technology
  products
• Independent non-profit corporation to collect and
  organize past, present and future BioSciCon
  activities for the advancement of education and
  science on womens health.

14
Acknowledgement

• The National Institutes of Health
• NIH SBIR Program (1R43CA86767-01, 1R43CA094628
  01, 2R44CA086767-02)
• NIH Commercialization Assistance Program
• Larta Institute, San Francisco, CA

15
BioSciCon, Inc. MarkPap, LLC 14905 Forest
Landing Circle Rockville, MD 20850 Shady Grove
Development Park, Gaithersburg, MD
20877 Frederick Innovation Technology Center,
Frederick, MD 21701 TeL
301-61-9130 Fax [phone] Web site
www.bioscicon.com E-mail info_at_bioscicon.com